Benjamin Hébraud

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

Murielle Roussel, Valérie Lauwers‐Cancès, Nelly Robillard et al. · Journal of Clinical Oncology · 2014 · 263 citations · Full text

Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults

M.L. Piel-Julian, Matthieu Mahévas, Johanne Germain et al. · Journal of Thrombosis and Haemostasis · 2018 · 132 citations · Full text

Platelet Count Threshold, Immune Thrombocytopenia Adults, Thrombosis +16

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Thierry Façon, Gordon Cook, Saad Z. Usmani et al. · Leukemia · 2022 · 117 citations · Full text

Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells

Cédric Menard, Joëlle Dulong, David Roulois et al. · Stem Cells · 2019 · 103 citations · Full text

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Benjamin Hébraud, Xavier Leleu, V. Lauwers‐Cancès et al. · Leukemia · 2013 · 102 citations

Hematological Malignancy, Ifm Experience, Medicine +7